

# How to Use Clinical Data in Medical Device Submissions in the EU & US

LIVE

Webinar January 17th 2023 | 15 CET / 9 am ET

## Presenters



**Jon I. Bergsteinsson**  
Co-Founder



**Mary Kay Sobcinski**  
Sr. Director Strategic Consulting



**Kim van Noort**  
Senior Medical Writer

# Overcome Common Pitfalls and Optimize Your Cross-Atlantic Clinical Strategy




**Mary Kay Sobcinski**  
Sr. Director Strategic  
Consulting



**Jon I. Bergsteinsson**  
Co-Founder



**Kim van Noort**  
Senior Medical Writer




acquired by Greenlight Guru Q2 2022

**Built for MedTech.**  
**Trusted by MedTech.**

The leading cloud-based platform  
to manage quality processes,  
product development, and  
clinical data.



Integrated global, full-service CRO with specialized expertise in medical device, novel technology, and combination products.



# Why This Topic?

Risk of products not getting approval (risk of product disapproval)

Too many manufacturers are forced to extend or repeat clinical studies.

Resulting in frustration, prolonged time-to-market, and missed revenue targets.

# Strategy Development for Multiple Geographies

---

Strategies and tactics



# Strategy Development for Multiple Geographies

## Priority

Define your regulatory, marketing, and reimbursement goals.

## Regulatory Approval

The first step, not the ultimate/only goal.

## Multi-Team Effort

Clinical and regulatory program development is a multi-step and multi-team effort.

# Program Development for Multiple Geographies

- ▶ Understand the regulatory and reimbursement requirements of each geography
- ▶ What product life-cycle stage is the device in, by geography?
- ▶ What do end users want to know to adopt the device?
- ▶ Are my marketing claims the same in all geographies?
- ▶ What are the project timelines and budgets?





# Clinical Strategy for Multiple Geographies

---

Consider the optimum study  
design for each geography

- ▶ Pre-approval vs post-approval studies
- ▶ Regulatory considerations, e.g. US Federal Regulations, ISO14155, GDPR
- ▶ Endpoints for regulatory approval, marketing claims, and reimbursement coverage

# Diving In

## Statistical Considerations

- Endpoint development; regulatory, marketing, reimbursement
- Data poolability across studies and geographies

## Protocol Development for Multiple Geographies

- Regulations and guidances
- Medical practice patterns
- Population similarities and differences

# Combining Clinical Strategies in Multiple Geographies

---

From complex to efficient

# Combining Clinical Strategies for Multiple Geographies

## Classification

Does your device(s) have  
similar classification

## Indication, Purpose, Benefit

Difference in indication,  
intended purpose and  
intended clinical benefit

## Equivalence

Can you claim equivalence vs  
substantial equivalence

# Clinical Data

## Data in Region?

Is there any data in the region that can be used, how?

## What is Needed?

What clinical data is needed in each region to meet the requirements for regulatory, marketing, and sales?


# Pre- and Post-Market Studies (EU/US)



Overlap between the US and the EU



Determine how most cost effectively you can use data from one region in the other region



# Keeping the Head Above Regulatory Differences

---


Overcoming common pitfalls with legal issues



# Data Processing Consent

- ▶ Data processing consent (GDPR) must be collected from EU citizens (not integrated into ICF)
- ▶ Subject data collected on EU citizens cannot be transferred to the US without consent
- ▶ No US law that prohibits data transfer to the EU (CCPA might require data consent)

California Consumer Privacy Act



# Good Clinical Practice

---



- ▶ EU MDR enforces "Good Clinical Practice" for Clinical Investigations
- ▶ Standard to follow in EU is ISO 14155:2020
- ▶ Local ethical requirements can differ within EU and outside of EU in Europe

# Good Clinical Practice

---



- ▶ FDA enforces "Good Clinical Practice" for Clinical Investigations
- ▶ FDA defines "Good Clinical Practice" as 21 CFR 50, 54, 56, 812; Part 11
- ▶ ISO 14155:2020 can be used to comply with 21 CFR 812.28

# Time for

---

# Q&A



Your product is important,  
and your trial deserves the team that has  
what it takes.

**It Takes Avania.**

For more information about multi-geography  
clinical strategy, reach out to us at:

[avaniaclinical.com](https://avaniaclinical.com)



**SMART-TRIAL<sup>®</sup>**  
*by greenlight guru*

---

## The Bridge Between Medical Devices and Clinical Data

Schedule a personalized demo at

[smart-trial.com/demo](https://smart-trial.com/demo)